Navigation Links
Pacira Pharmaceuticals, Inc. Reports First Quarter 2011 Financial Results
Date:5/11/2011

nd, parallel group, placebo-controlled bunionectomy trial was presented at the 2011 American Academy of Orthopaedic Surgeons Annual Meeting and the Orthopaedic Research Society's 57th Annual Meeting. The data demonstrated that the median time to first use of opioid rescue medication was 7.2 hours for patients treated with EXPAREL compared with 4.3 hours for patients on placebo (p<0.0001) and that patients treated with EXPAREL had comparable safety in wound healing and significantly improved efficacy in pain reduction compared to patients treated with placebo.  
  • Completed an IPO:  On February 8, 2011, Pacira sold an aggregate of 6 million shares of its common stock at $7.00 per share resulting in 2011 net proceeds of approximately $37 million.
  • Presented new Phase 1 study data on subjects with hepatic impairment: In March 2011, data from Pacira's Phase 1 study evaluating EXPAREL in subjects with moderate, stable hepatic impairment was presented at the 2011 American Society for Clinical Pharmacology and Therapeutics 112th Annual Meeting. Results from the Phase 1 open-label, parallel group volunteer study demonstrated that the differences in plasma exposure of EXPAREL between subjects with moderate, stable hepatic impairment compared to subjects with normal hepatic function were small and unlikely to require a dose adjustment of EXPAREL.
  • Presented new preclinical study data on the administration of EXPAREL via peripheral nerve block and on the compatibility of EXPAREL with Lidocaine: In April 2011, new data from two preclinical studies were presented at the Experimental Biology 2011 Annual Meeting. Results from the two preclinical studies demonstrated that EXPAREL was safe when administered in animals as peripheral nerve block and that EXPAREL may be locally administered after waiting 20 minutes following local administration of lidocaine, without potential for an interaction. Additional studies are underway to
    '/>"/>

  • SOURCE Pacira Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations
    2. Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2011 Financial Results Webcast and Conference Call
    3. Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
    4. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
    5. Pacira Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
    6. Pacira Pharmaceuticals EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting
    7. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
    8. Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
    9. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
    10. Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
    11. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/22/2014)... - On Aug. 20, at its annual meeting in ... (CMA) voted on and approved a delegate resolution opposing ... Bedrocan Cannabis Corp., a leading Canadian licensed producer of ... The CMA is quite right to point out ... plant material, including medicinal cannabis. While some patients, particularly ...
    (Date:8/22/2014)... Research and Markets  has announced the addition of ... Technologies" report to their offering. ... you wish to expand your product line, you,ll know ... authors know you want to make effective product development ... improved revenues and take market share from your competition. ...
    (Date:8/22/2014)... 22, 2014  Dr. Mark Rasak , MD ... Lifetime Achievement Award in the field of Medicine as ... Clinical Associates. Dr. Rasak has over 15 ... aspects of the business; overseeing the daily operations; interventional ... intervention. In addition, he is an honored Fellow of ...
    Breaking Medicine Technology:Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 3Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2
    ... 2011 EMKinetics, Inc. announced today initiation of ... trial for patients suffering from urge incontinence and ... at 10-15 US centers.  Submission for CE mark ... the study.   EMKinetics, TranStim therapy builds on ...
    ... 2011 Masimo (NASDAQ: MASI ) announced ... period ended October 1, 2011, after the market closes on October ... at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted ... de Raad, Executive Vice President and Chief Financial Officer. ...
    Cached Medicine Technology:EMKinetics Announces Start of Pivotal Trial for the TranStim™ Transdermal Neuromodulation System 2Masimo to Report Third Quarter 2011 Financial Results After Market Close on October 25, 2011 2Masimo to Report Third Quarter 2011 Financial Results After Market Close on October 25, 2011 3
    (Date:8/22/2014)... first time an oncogenic somatic mutation at amino acid ... been identified in small cell lung cancer (SCLC) tumors ... lines produced increased intracellular signaling and cell growth. , ... representing 15% of all lung cancers and is strongly ... cancer, has been extensively examined for genomic alterations and ...
    (Date:8/22/2014)... Paying tuition and other related educational expenses ... for four nurse educators pursuing advanced degrees, thanks to ... Foundation for Nursing Education . This year’s recipients – ... than in 2013, thanks to these named NLN Foundation ... Marcil Endowment Funds, both donated by Kathy Mershon; the ...
    (Date:8/22/2014)... New York, New York (PRWEB) August 22, 2014 ... ) continue to be filed in U.S. courts ... cardiovascular events due to their use of prescription ... to court documents, a new claim was filed ... California man who allegedly suffered life-threatening heart issues ...
    (Date:8/22/2014)... (PRWEB) August 22, 2014 CarePoint ... specialist in Internal Medicine, Geriatrics, Hospice and Palliative ... CarePoint Health Medical Group. Their system welcomes Dr. ... and experienced physicians comprise CarePoint Health Medical Group, ... in Hudson County, representing a wide range of ...
    (Date:8/22/2014)... 2014 (HealthDay News) -- Back-to-school time provides an opportunity ... into the family schedules, an expert suggests. "Forget ... year can also be the start of a new ... professor of kinesiology at the University of the Sciences ... With kids, extracurricular activities likely to build up, "it,s ...
    Breaking Medicine News(10 mins):Health News:Novel oncogenic RET mutation found in small cell lung cancer 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Dr. Reisner Joins CarePoint Health Medical Group 2Health News:With Kids in School, Parents Can Work Out 2
    ... Rheumatism (EULAR) welcomes the outcomes of yesterday,s Council of ... 7 December, ministers for health adopted Council Conclusions on ... States and the European Commission to adopt concrete, coordinated ... pleased to note that the Council Conclusions reflect many ...
    ... (HealthDay News) -- ,Women with localized breast cancer are less ... surgery, a new study finds. The researchers also found ... of the recurrence of localized cancer. The three-nation study ... common type of noninvasive breast cancer, who were followed for ...
    ... MDA recent study accepted for publication in The Endocrine ... (JCEM) has demonstrated a novel and accurate test for ... in 1,500 to 2,000 female live births and early ... and co-morbid conditions including cardiac and renal problems. ...
    ... CA (December 8, 2010) People who are neurotic often ... neurotic newlyweds have frequent sexual relations, their marital satisfaction ... counterparts, according to a study in the current ... Neuroticism is the tendency to experience negative ...
    ... HealthDay Reporter , TUESDAY, Dec. 7 (HealthDay News) -- Stool ... accurate for patients on a low-dose aspirin regimen, which is ... While therapeutic aspirin use was once feared to skew ... researchers found the test was significantly more sensitive for low-dose ...
    ... can be a life saver for patients needing immediate ... the process of activating them often delays treatment beyond ... print in Annals of Emergency Medicine, was ... multicenter, retrospective chart review, McMullan found that a majority ...
    Cached Medicine News:Health News:EULAR welcomes Council action to tackle chronic diseases 2Health News:Radiation After Surgery Lowers Chances of Breast Cancer's Return 2Health News:Frequent sex protects marital happiness for neurotic newlyweds 2Health News:Low-Dose Aspirin Boosts Accuracy of Colon Cancer Test 2Health News:Low-Dose Aspirin Boosts Accuracy of Colon Cancer Test 3Health News:Even with helicopter EMS, hospital transfer can delay treatment for heart attacks 2Health News:Even with helicopter EMS, hospital transfer can delay treatment for heart attacks 3
    Used to introduce large devices for vascular intervention....
    Used for the introduction of catheters, balloons and other vascular devices....
    Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
    Sheath Introducer featuring patented SLIX Valve, rotating collar, kink-resistant cannula and atraumatic tip transitions....
    Medicine Products: